Supplier Type
- Manufacturer
- contract manufacturer
- custom synthesis
- Trader
- Reagent
Supplier Region
- Hyderabad(7)
- Maharashtra(2)
- Vadodara(1)
- Gujarat(4)
- Mumbai(4)
- Ahmedabad(2)
- Pune(2)
- Punjab(1)
- Karnataka(1)
- Nagpur(1)
Purity
- Salicylic Acid
- Rasagiline Mesylate Impurity C
- NLT95%
- NLT 95%
- NLT 90%
- more than 95%
- more than 90%
- Mesalazine EP Impurity H
- Mathadone (M225865) impurity. Used in synthesis of methadone, antispasmodics and other pharmaceutica
- Greater than 99%
- Empagliflozin intermediate, Dapagliflozin Impurity
- Dipropargyl r- amino indane
- Dapagliflozin Intermediate, Dapagliflozin Impurity
- API Impurity / In-house working standard
- Acetylsalicylic Acid EP Impurity C
- 99.99%
- 99.98%
- 99.95%
- 99.91%
- 99.86%
- 99.85%
- 99.73%
- 99.42%
- 99.29%
- 99%
- 98.60%
- 98.12%
- 98%
- 97-99%
- 97-99 %
- 97.57%
- 97%
- 97 %
- 96.80%
- 96.39%
- 96.14%
- 96%
- 95.48%
- 95%
- >95%
- >92%
- 90%
- >90%
- 25 MG 50 MG 100 MG 250 MG EXTRA
- (R)-N,N-di(prop-2-yn-1-yl)-2,3- dihydro-1
Package
- 2.5501e+00925 MG 50 MG 100 MG 250 MG EXTRA
- 2.5501e+00925 MG 50 MG 100 MG 250 MG EXTRA
- 25MG
- 1g
- 5g
- 25g
- 1kg
- 5kg
- 10kg
- 25kg
- 50kg
- 1MT
- 95NLT %
-
4-Chloromethyl-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
404844-11-7
-
Imatinib
152459-95-5
-
Imatinib mesylate
220127-57-1
-
1-(3-Pyridyl)-3-(dimethylamino)-2-propen-1-one
55314-16-4
-
iMatinib related substance C
938082-57-6
-
Medicine Grade Imatinib Mesylate Capsules
-
Iloperidone iMpurity
1375651-23-2
-
1-[2-[4-Hydroxy-3-(2-hydroxyethyl)phenyl]ethyl]-α,α-diphenyl-
215032-24-9
-
Atenolol impurity
-
EzetiMibe iMpurity
2499943-55-2
1Y
Hyderabad
Product catalog:
44
Nagpur
Product catalog:
2
Diphenyl Acetonitrile, C14H11N, Cas Number: 86-29-3 86-29-3
Reagent
Note:Purity: Mathadone (M225865) impurity. Used in synthesis of methadone, antispasmodics and other pharmaceutica | Package: 1Kg;INR
Reagent
Note:Purity: Dapagliflozin Intermediate, Dapagliflozin Impurity | Package: 1Kg;INR
Gujarat
Product catalog:
23





